RecruitingNot ApplicableNCT04349657

A Study Evaluating the Endovascular Treatment of Subjects with Stenotic or Restenotic Lesions of the Common Femoral Artery with the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy

An RCT Evaluating the Safety and Efficacy of the Endovascular Treatment of Subjects with Stenotic or Restenotic Lesions of the Common Femoral Artery with the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy


Sponsor

ID3 Medical

Enrollment

286 participants

Start Date

May 5, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The SUPERSURG RCT trial investigates the efficacy and safety of the endovascular treatment of stenosis or restenosis in the common femoral artery (CFA) of patients presenting with Rutherford classification 2,3 or 4 with a Supera Vascular Mimetic Implant of Abbott, compared to classic surgical common femoral artery endarterectomy. The Supera Vascular Mimetic Implant has an interwoven design and has a high crush resistance and is, when correctly implanted, an ideal stent to treat eccentric calcified plaques in the CFA. An expected total of 143 patients will be treated with the Vascular Mimetic Implant of Abbott and compared to a control group of another 143 patients that will be treated with classic surgical endarterectomy of the common femoral artery. Assignment to the treatment groups will be at random. Patients will be invited for a follow-up visit at 1, 6, 12, 24 and 36 months post-procedure. The primary efficacy endpoint is defined as follows: freedom from clinically-driven target lesion revascularization and binary restenosis at 12 months. The primary safety endpoint is defined as follows: a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularisation and wound related complications through 30 days post-index procedure. The secondary endpoints are defined as technical success, primary patency in the deep femoral artery, primary patency in the target lesion, target lesion revascularisation, target vessel revascularisation, binary restenosis, duration of initial hospital stay, sustained clinical improvement, change of walking impairment questionnaire score from baseline, change in target limb Rutherford classification, change in target limb ABI/TBI from baseline, all cause death, thrombosis at the target lesion through 6, 12, 24 and 36 months post-procedure.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Endarterectomy treatment group and a medical device called Supera Peripheral Stent System treatment group for people with peripheral arterial disease. The study is currently recruiting participants at 13 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESupera Peripheral Stent System treatment group

Percutaneous endovascular stenting with the Supera Peripheral Stent System

PROCEDUREEndarterectomy treatment group

Surgical treatment through endarterectomy


Locations(13)

O.L.V. Hospital

Aalst, Belgium

Imelda Hospital

Bonheiden, Belgium

A.Z. Sint-Blasius

Dendermonde, Belgium

Z.O.L.

Genk, Belgium

Az Groeninge

Kortrijk, Belgium

AZ Sint-Maarten

Mechelen, Belgium

A.Z. Jan Portaels

Vilvoorde, Belgium

Maastricht UMC+

Maastricht, Limburg, Netherlands

Dijklander hospital

Hoorn, North Holland, Netherlands

St Antonius Hospital

Utrecht, Utrecht, Netherlands

Noordwest ziekenhuisgroep

Alkmaar, Netherlands

Bonifraterskie Centrum Medyczne

Krakow, Poland

Karol Marcinkowski Medical University

Poznan, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04349657


Related Trials